Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 15 (8), 476-95

Long-acting Medications for the Hyperkinetic Disorders. A Systematic Review and European Treatment Guideline

Affiliations
Review

Long-acting Medications for the Hyperkinetic Disorders. A Systematic Review and European Treatment Guideline

Tobias Banaschewski et al. Eur Child Adolesc Psychiatry.

Abstract

A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.

Similar articles

See all similar articles

Cited by 122 PubMed Central articles

See all "Cited by" articles

References

    1. MedGenMed. 2006 Oct 05;8(4):4 - PubMed
    1. Biol Psychiatry. 2000 Jul 1;48(1):9-20 - PubMed
    1. Biol Psychiatry. 2003 Jan 15;53(2):112-20 - PubMed
    1. Clin Evid. 2002 Jun;(7):896-905 - PubMed
    1. J Am Acad Child Adolesc Psychiatry. 2000 Nov;39(11):1424-31 - PubMed

MeSH terms

Substances

Feedback